Annual revenue went from KRW 47.8 billion in 2022 to KRW 47.1 billion in 2023, down 1.4%, then rose to KRW 52.5 billion in 2024 (up 11.4%) and KRW 56.6 billion in 2025 (up 7.8%). Revenue has grown for two consecutive years, and 2025 was the largest year of 2022 to 2025.
Operating profit was KRW 1.7 billion in 2022, the smallest year at KRW 880 million in 2023 (down 48.4%), then KRW 2.47 billion in 2024 (up 180.9%), the largest year of the four. It fell 36.3% to KRW 1.57 billion in 2025. Operating margin was 3.6% in 2022, 1.9% in 2023, 4.7% in 2024 and 2.8% in 2025.
Revenue peaked in 2025, but the margin was lower than in 2024, so top-line growth did not translate into higher profit.
The net loss attributable to controlling shareholders was KRW 9.64 billion in 2022, KRW 2.4 billion in 2023, KRW 21 billion in 2024 and KRW 4.1 billion in 2025, and the net loss including non-controlling interests followed the same pattern.
In its 2025 year-end settlement the company said it had reflected a substantial part of the value decline on its earlier Liminatus Pharma investment, as reported in May 2026.
Operating cash flow went from KRW 8.46 billion in 2022 to -KRW 56.55 million in 2023 and -KRW 961 million in 2024, then turned to KRW 2.74 billion in 2025.
By quarter, Q3 2025 showed revenue of KRW 15.6 billion, operating profit of KRW 1.06 billion and net income attributable to controlling shareholders of KRW 597 million. There is no quarterly figure for Q4 2025 in the periodic filings, leaving a gap in the sequence.
Q1 2026 revenue dropped to KRW 8.55 billion, with an operating loss of KRW 859 million and a net loss attributable to controlling shareholders of KRW 1.54 billion.
Q2 2026 revenue recovered to KRW 15.5 billion (up 81.5% from the prior quarter), with operating profit of KRW 1.34 billion and net income attributable to controlling shareholders of KRW 1.06 billion. Q3 2026 revenue of KRW 11.8 billion fell 24.3% from the prior quarter and 24.5% from a year earlier.
Operating profit of KRW 259 million was down 75.7% year on year, while net income attributable to controlling shareholders of KRW 843 million rose 41.3%, so operating profit and that net income moved in opposite directions.
Net income attributable to controlling shareholders for the latest four quarters (Q4 2025 to Q3 2026) totaled KRW 499 million.